Malignant News and Research

RSS

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

29 Aug 2012

Scientists identify genes that underlie growth of primitive leukemia stem cells

University of Rochester Medical Center scientists believe they are the first to identify genes that underlie the growth of primitive leukemia stem cells, and then to use the new genetic signature to identify currently available drugs that selectively target the rogue cells.

29 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Renal denervation improves blood pressure and arterial stiffness in patients with therapy resistant hypertension, according to research presented at ESC Congress 2012 by Mr Klaas Franzen from the University Hospital of Schleswig-Holstein.

28 Aug 2012

Control of siRNA could aid regenerative medicine, cancer therapy

Some of the body's own genetic material, known as small interfering RNA (siRNA), can be packaged then unleashed as a precise and persistent technology to guide cell behavior, researchers at Case Western Reserve University report in the current issue of the journal, Acta Biomaterialia.

28 Aug 2012

Patients tend to have worse outcomes when GBM appears in more than one location

When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.

27 Aug 2012

PHF20 transcriptional factor plays a unique role in regulating p53

Researchers at Moffitt Cancer Center and colleagues have identified PHF20, a novel transcriptional factor, and clarified its role in maintaining the stability and transcription of p53, a gene that allows for both normal cell growth and tumor suppression. PHF20, the researchers found, plays a previously unknown and unique role in regulating p53.

24 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

New model more effective in predicting individuals at high risk of lung cancer

A lung cancer risk prediction model developed by scientists at the University of Liverpool has been shown to be a viable tool for selecting high risk individuals for prevention and control programmes.

21 Aug 2012

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Genomic deletions promote cancer by carving up or eliminating tumor-suppressor genes, but now scientists report in the journal Nature that the collateral damage they inflict on neighboring genes exposes cancer cells to vulnerabilities and new avenues for attack.

16 Aug 2012

Malignant mesothelioma diagnosis with an E-nose: an interview with Associate Professor Deborah Yates, UNSW

Malignant mesothelioma is a rare tumor of the pleura which is the lining of the inside of the chest wall. It is highly linked with asbestos exposure.

16 Aug 2012

Inhibiting over-production of Panx1 protein can treat melanoma

New research from Western University, Canada, has identified a potential new target for the treatment of melanoma, the deadliest of all skin cancers. Silvia Penuela and Dale Laird discovered a new channel-forming protein called Pannexin (Panx1) that is expressed in normal levels on the surface of healthy skin cells.

16 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Mechanism for chemotherapy resistance identified

Researchers have identified that chemotherapy induces subsequent treatment resistance through damaging healthy tissue, which in turn secretes novel factors that sustain the growth of residual tumor cells.

15 Aug 2012

HAS-BLED proves predictive ability

Researchers say that the HAS-BLED score is a significant predictor for intracranial hemorrhage when compared with the HEMORR2HAGES and ATRIA scores, supporting international guideline recommendations.

14 Aug 2012

Heartburn and cancer: an interview with Mindy Mintz Mordecai

What most of us think of as heartburn is a symptom of Reflux Disease or GERD (Gastroesophageal Reflux Disease). It’s that burning discomfort an individual experiences when stomach acids and other fluids come back up into their esophagus.

14 Aug 2012

Researchers identify key element in the development of Burkitt lymphoma

Burkitt lymphoma is a malignant, fast-growing tumor that originates from a subtype of white blood cells called B lymphocytes of the immune system and often affects internal organs and the central nervous system. Now Dr. Sandrine Sander and Professor Klaus Rajewsky of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have identified a key element that transforms the immune cells into malignant lymphoma cells.

14 Aug 2012

Researchers uncover how pathological cells activate themselves in chronic lymphocytic leukaemia

Researchers in the group of Prof. Dr. Hassan Jumaa, Centre for Biological Signalling Studies (BIOSS) of the University of Freiburg, Department for Molecular Immunology, have identified a new mechanism that causes immune cells to convert into malignant cancer cells.

13 Aug 2012

Recurrences of ovarian cancer can be detected earlier and more accurately with PET/CT

Due to the lack of studies, there is currently no proof that patients with ovarian cancer can benefit from positron emission tomography (PET) alone or in combination with computed tomography (CT). As regards diagnostic accuracy, in certain cases, recurrences can be detected earlier and more accurately with PET or PET/CT than with conventional imaging techniques.

9 Aug 2012

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

9 Aug 2012

Malignant News and Research

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Scientists identify genes that underlie growth of primitive leukemia stem cells

Eplerenone shown to reduce cumulative heart failure hospitalisations

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Control of siRNA could aid regenerative medicine, cancer therapy

Patients tend to have worse outcomes when GBM appears in more than one location

PHF20 transcriptional factor plays a unique role in regulating p53

New results describe development of DC cancer vaccine with enhanced immunogenic potential

New model more effective in predicting individuals at high risk of lung cancer

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Malignant mesothelioma diagnosis with an E-nose: an interview with Associate Professor Deborah Yates, UNSW

Inhibiting over-production of Panx1 protein can treat melanoma

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Mechanism for chemotherapy resistance identified

HAS-BLED proves predictive ability

Heartburn and cancer: an interview with Mindy Mintz Mordecai

Researchers identify key element in the development of Burkitt lymphoma

Researchers uncover how pathological cells activate themselves in chronic lymphocytic leukaemia

Recurrences of ovarian cancer can be detected earlier and more accurately with PET/CT

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News